IRIS
ARBITRIO, Mariamena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.367
AS - Asia 1.021
EU - Europa 789
SA - Sud America 173
Continente sconosciuto - Info sul continente non disponibili 116
AF - Africa 48
OC - Oceania 7
Totale 3.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.306
IT - Italia 425
SG - Singapore 373
CN - Cina 170
BR - Brasile 129
IN - India 117
GB - Regno Unito 93
DE - Germania 89
VN - Vietnam 77
HK - Hong Kong 55
BD - Bangladesh 45
CA - Canada 37
FI - Finlandia 37
ID - Indonesia 28
PK - Pakistan 26
SE - Svezia 24
JO - Giordania 23
NL - Olanda 21
SA - Arabia Saudita 18
MX - Messico 16
FR - Francia 14
ES - Italia 13
IQ - Iraq 12
RU - Federazione Russa 12
ZA - Sudafrica 11
CO - Colombia 10
EG - Egitto 10
TR - Turchia 10
UA - Ucraina 10
CZ - Repubblica Ceca 9
MY - Malesia 8
EC - Ecuador 7
IE - Irlanda 7
IR - Iran 7
JP - Giappone 7
LT - Lituania 7
NG - Nigeria 7
PE - Perù 7
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
AR - Argentina 6
AU - Australia 6
KE - Kenya 6
KR - Corea 6
ET - Etiopia 5
LB - Libano 5
MA - Marocco 5
RO - Romania 5
UZ - Uzbekistan 5
VE - Venezuela 5
CY - Cipro 4
EU - Europa 4
PH - Filippine 4
BG - Bulgaria 3
CL - Cile 3
GT - Guatemala 3
HR - Croazia 3
PL - Polonia 3
PS - Palestinian Territory 3
PY - Paraguay 3
CH - Svizzera 2
HN - Honduras 2
LK - Sri Lanka 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AT - Austria 1
AZ - Azerbaigian 1
BO - Bolivia 1
CM - Camerun 1
GE - Georgia 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MD - Moldavia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
SC - Seychelles 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 3.410
Salva come PNG Salva come JPEG
Città #
San Jose 247
Singapore 180
Ashburn 146
Chandler 124
Santa Clara 67
Dallas 64
Munich 62
Chicago 49
Bengaluru 46
Hefei 46
London 45
Hong Kong 43
Beijing 40
Ho Chi Minh City 36
Council Bluffs 32
Milan 30
Catanzaro 26
New York 25
Turku 25
Lawrence 24
Princeton 24
Los Angeles 21
Naples 21
Amman 15
Jeddah 13
São Paulo 13
The Dalles 13
Boardman 12
Carbonia 12
Helsinki 12
Parma 12
Montreal 11
Chennai 10
Hanoi 10
Ottawa 10
Rome 10
San Nicola Manfredi 10
Spezzano della Sila 10
Wilmington 10
Atlanta 9
Bologna 9
Delhi 8
Irbid 8
Madrid 8
Brooklyn 7
Frankfurt am Main 7
Kaunas 7
San Francisco 7
Santo Stefano di Rogliano 7
Buffalo 6
Cosenza 6
Da Nang 6
Ercolano 6
Seattle 6
Stockholm 6
Afragola 5
Cardiff 5
Des Moines 5
Dhaka 5
Glasgow 5
Hyderabad 5
Kuala Lumpur 5
Kyiv 5
Lucknow 5
Nairobi 5
Olomouc 5
Pune 5
Redmond 5
Riyadh 5
Sacramento 5
Tashkent 5
Tokyo 5
Addis Ababa 4
Ankara 4
Brescia 4
Catania 4
Charlotte 4
Dublin 4
Florianópolis 4
Islamabad 4
Johannesburg 4
Lahore 4
Manchester 4
Marano Marchesato 4
Messina 4
Mexico City 4
Nicosia 4
Paris 4
Redwood City 4
Richmond 4
Shanghai 4
Tanta 4
Thái Bình 4
Tubarão 4
West Jordan 4
Acquaviva delle Fonti 3
Ajman 3
Banyumas 3
Belo Horizonte 3
Berlin 3
Totale 1.911
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 497
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 146
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 119
miR-22 suppresses DNA ligase III addiction in multiple myeloma 108
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 102
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 98
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 82
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 79
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 78
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 78
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 77
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 76
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 74
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 71
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 69
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 69
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 68
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 65
Autophagy and neuroprotection in astrocytes exposed to 6-hydroxydopamine is negatively regulated by NQO2: relevance to Parkinson’s disease 62
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 61
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 60
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 60
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 60
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 60
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 59
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 57
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 57
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 56
Integration of DNA Microarray with Clinical and Genomic Data 53
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 52
Mmrf-commpass data integration and analysis for identifying prognostic markers 52
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 52
Ethical Perspectives on Pharmacogenomic Profiling 51
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 50
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 49
Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity 48
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 47
Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS 44
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 33
null 31
Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future 30
Upregulation of ACHE and BACE2 genes by oleacein in Alzheimer's disease and neuroblastoma 19
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 14
null 2
Totale 3.521
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.500
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.500
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022126 0 0 0 22 5 2 10 22 30 17 13 5
2022/2023376 54 28 29 10 42 30 5 28 40 42 47 21
2023/2024469 87 34 42 37 41 70 27 38 10 17 32 34
2024/2025843 74 20 28 42 51 109 51 53 51 22 149 193
2025/20261.502 102 147 128 164 148 76 202 83 160 137 97 58
2026/2027108 42 66 0 0 0 0 0 0 0 0 0 0
Totale 3.521